This is the first of a series of podcasts from the two hour special webinar we did in partnership with the LUNGevity Foundation at the Santa Monica "Targeted Therapies in Lung Cancer" meeting several weeks ago.  There, I was privileged to be joined by four excellent guest faculty members -- Dr.

Here's the second talk from our recent webinar, partnering with LUNGevity Foundation to cover the ASCO Highlights in Lung Cancer, and this talk followed after

Recently, I described the rationale for targeting HER2 mutations in non-small cell lung cancer (NSCLC). Most of our experience with HER2 targeted therapy comes from studies in breast cancer. Now, I'd like to introduce you to BRAF, another novel target in NSCLC that is a central component in cell signalling, growth, and division.

In a terrific podcast done a year ago about molecular markers in lung cancer and moving beyond a "one size fits all approach", Dr.